ImmunoGen Appoints Mark J. Enyedy as President and Chief Executive Officer
April 26 2016 - 8:00AM
Business Wire
– Proven leader with deep experience building
oncology businesses –
ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company
developing targeted cancer therapeutics using its proprietary
antibody-drug conjugate (ADC) technology, today announced that Mark
J. Enyedy has been appointed President and CEO and elected to the
Board of Directors, effective May 16, 2016. Mr. Enyedy succeeds
Daniel Junius, who as previously announced is retiring from these
positions and will continue to serve on ImmunoGen’s Board.
“Today, ImmunoGen has a rich pipeline of wholly-owned oncology
product candidates, validated technology, and strong research,”
said Stephen McCluski, Chairman of the Board. “Mark’s proven
leadership skills, combined with his deep experience building
science-based oncology businesses, make him ideally suited to take
ImmunoGen to the next level.”
Mr. Enyedy, 52, brings over 25 years of combined general
management, business development and legal experience in the
biotechnology industry. He joins ImmunoGen from Shire plc, where he
served as Executive Vice President and Head of Corporate
Development, leading the company’s Strategy, M&A, and Corporate
Planning functions and providing commercial oversight for the
company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as
CEO of Proteostasis Therapeutics, Inc., following 15 years at
Genzyme Corporation in diverse roles, most recently as President of
the Transplant, Oncology, and Multiple Sclerosis divisions. During
his tenure at Genzyme, Mr. Enyedy developed and executed the
company’s strategy to enter the oncology market, overseeing the
launch of two new products and managing a global business
generating over $675 million in revenue with operations in more
than 50 countries.
Before joining Genzyme, Mr. Enyedy was an associate with the
Boston law firm Palmer & Dodge. He holds a J.D. from Harvard
Law School and a B.S. from Northeastern University. Mr. Enyedy also
serves on the Board of Directors of Fate Therapeutics.
“I am pleased to be joining ImmunoGen at such an important time
in the Company’s evolution and helping to build upon its leadership
position in the exciting ADC field,” said Mr. Enyedy. “With a lead
product in later-stage testing for ovarian cancer, a strong
portfolio of earlier-stage candidates, and a productive technology
platform, ImmunoGen is well-positioned for sustainable innovation
in oncology and value creation for shareholders. I look forward to
working with the company’s outstanding leadership team, dedicated
employees, and global partners to develop and commercialize novel
ADC therapies, which hold the potential to deliver better outcomes
for cancer patients across an expanding range of indications.”
“It has been a privilege to serve as the CEO of ImmunoGen over
these past seven years, and I am delighted to have Mark as my
successor,” said Mr. Junius. “Mark’s experience, vision, and
leadership skills will enable ImmunoGen to realize its full
potential in developing better therapies for cancer patients.”
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted anticancer therapeutics using its proprietary ADC
technology. The Company has four wholly owned clinical-stage ADCs.
The lead, mirvetuximab soravtansine, is in Phase 2 testing for the
treatment of folate receptor α-positive ovarian cancer. ImmunoGen's
ADC technology is used in Roche's marketed product, Kadcyla®, and
in agents in development by partners Amgen, Bayer, Biotest, CytomX,
Lilly, Novartis, Sanofi and Takeda. More information about the
Company can be found at www.immunogen.com.
ImmunoGen Forward-Looking Statement
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer agents. A review of these risks can be found in
ImmunoGen's Annual Report on Form 10-K for the fiscal year ended
June 30, 2015 and other reports filed with the Securities and
Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160426005304/en/
ImmunoGen, Inc.For Investors:Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Michael
Lampe,484-575-5040michael@scientpr.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2023 to May 2024